Systemic inflammation markers-including NLR, C-reactive protein (CRP), and lactate dehydrogenase (LDH)-are increasingly recognized as prognostic indicators in NSCLC, reflecting tumor-associated inflammation and metabolic dysregulation. The gene discussed is CRP; the disease is neoplasm.